1
|
Drai RV, Mayorov AY, Karonova TL, Parfenova TM, Makarenko IE, Magruk MA, Alpenidze DN, Kovalik VV, Zinnatulina BR, Grigorjeva IV, Andreeva AT. The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix ® 30 in Type 2 diabetes patients. J Comp Eff Res 2022; 11:1337-1347. [PMID: 36511777 DOI: 10.2217/cer-2021-0232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Aim: To evaluate the safety and efficacy of insulin Aspart-Mix biosimilar candidate GP40081 (GP-Asp30) compared with NovoMix® 30 (NN-Asp30). Materials & methods: In a randomized open-label, active-controlled, 26-week non-inferiority clinical trial 264 patients with Type 2 diabetes mellitus were randomized 1:1 to receive once-daily GP-Asp30 or NN-Asp30. The primary safety end point was the immune response rate. Efficacy outcomes were a mean change in HbA1c (primary), frequency of achieving a glycemic g fasting plasma glucose levels, 7-point glucose profiles, and insulin doses. Results: The immune response developed in 10/126 (8%) participants in the GP-Asp30 group and in 10/125 (8%) participants in the NN-Asp30 group (p = 1.000). The mean difference in HbA1c change between groups was 0.12 (95%CI [-0.14, 0.38]). Other secondary efficacy and safety outcomes weren't statistically different between the two groups. Conclusion: GP-Asp30 demonstrated similar safety and efficacy compared with NN-Asp30 and may be considered a biosimilar insulin.
Collapse
Affiliation(s)
- Roman V Drai
- R&D Center, GEROPHARM, Degtyarny Lane 11B, St. Petersburg, 191144, Russia
| | - Alexander Y Mayorov
- Endocrinology Research Centre, Dm. Ulyanova Street 11, Moscow, 117036, Russia
| | - Tatiana L Karonova
- Institute of Endocrinology, Almazov National Medical Research Center, Akkuratova Street 2, St. Petersburg, 197341, Russia
| | - Tatiana M Parfenova
- Krasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetskiy, Partizana Zheleznyaka Street 1, Krasnoyarsk, 660022, Russia
| | - Igor E Makarenko
- R&D Center, GEROPHARM, Degtyarny Lane 11B, St. Petersburg, 191144, Russia
| | - Maxim A Magruk
- R&D Center, GEROPHARM, Degtyarny Lane 11B, St. Petersburg, 191144, Russia
| | - Diana N Alpenidze
- City Polyclinic No. 117, Simonova Street 5/1, St. Petersburg, 194358, Russia
| | | | | | - Irina V Grigorjeva
- R&D Center, GEROPHARM, Degtyarny Lane 11B, St. Petersburg, 191144, Russia
| | - Alena T Andreeva
- Institute of Endocrinology, Almazov National Medical Research Center, Akkuratova Street 2, St. Petersburg, 197341, Russia
| |
Collapse
|
2
|
The Profile of Glucose Lowering Therapy in Persons with Type 2 Diabetes Mellitus in an Aging Russian Population. J Pers Med 2022; 12:jpm12101689. [PMID: 36294828 PMCID: PMC9604909 DOI: 10.3390/jpm12101689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 09/21/2022] [Accepted: 10/06/2022] [Indexed: 12/02/2022] Open
Abstract
We aimed to analyze the profile of glucose lowering therapy (GLT) in persons with diabetes mellitus type 2 (DM2) in an aging Russian population. A random population sample (n = 3898, men/women, 55−84) was examined in Novosibirsk, during 2015−2018 (HAPIEE Project). The design of the present work is a cross-sectional study. DM2 was defined in those with a history of DM2 receiving GLT, or at a level of fasting plasma glucose (FPG) ≥7.0 mmol/L. The entire DM2 group was included in the analysis (n = 803); of these, 476 persons were taking GLT and were included in the analysis at stage 2. Regular GLT medication intake for 12 months was coded with ATC. In studied sample, the prevalence of DM2 was 20.8%. Among subjects with DM2, 59% of individuals received GLT, 32% did not. Glycemic control (FPG < 7.0 mmol/L) was achieved in every fifth participant with DM2 (35% in those receiving GLT). In frequency of GLT use, biguanides ranked in first place (75%), sulfonylurea derivatives in second (35%), insulins in third (12%), and iDPP-4 in fourth (5%). Among those receiving GLT, 24% used combined oral therapy, and 6% used insulin-combined therapy. In conclusion, in a population sample aged 55−84 examined in 2015−2018, glycemic control was achieved in every fifth participant with DM2, and in every third participant receiving GLT. The proportion of participants using new GLT drugs was small, and there was a lack of HbA1c monitoring for intensive glycemic control.
Collapse
|
3
|
Alieva A, Alimov A, Khaidarova F, Ismailov S, Rakhimova G, Nazhmutdinova D, Shagazatova B, Tsareva V. Assessing the Effectiveness of Type 2 Diabetes Screening in the Republic of Uzbekistan. Int J Endocrinol Metab 2022; 20:e124036. [PMID: 36714191 PMCID: PMC9871961 DOI: 10.5812/ijem-124036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2022] [Revised: 09/13/2022] [Accepted: 10/09/2022] [Indexed: 11/05/2022] Open
Abstract
BACKGROUND Type 2 diabetes (T2D) screening should be performed continuously at the primary care level in order to prevent disabling complications. Due to the high prevalence of undiagnosed T2D in the Republic of Uzbekistan, a decision was made to implement a nationwide screening program for T2D. OBJECTIVES The current study, taking into account the limited resources of Uzbekistan's health care system, aimed to offer the most effective, simple, and economical option required for the actual implementation of regular T2D screening in the country's primary care. METHODS The screening was conducted from December 2018 to March 2019. There were four different scenarios, which differed in terms of eligibility criteria and the methodology adopted for detecting dysglycemia. RESULTS A total of 2,430 patients were examined in four months. The T2D diagnosis was established by an endocrinologist in 9.3% of the cases with one eligibility criterion and 15.9% of the cases with three eligibility criteria. The diagnosis of T2D was established by an endocrinologist in 11.7% of the cases with HbA1c screening and 13.5% of the cases with glucose screening. CONCLUSIONS The screening was feasible in Uzbekistan only in limited conditions. The reasonable strategy was found to be the screening for incidental glycemia in all patients with at least one T2D risk factor. It was recommended that patients with incidental glycemia ≥ 7.8 mmol/L should be tested for fasting glycemia.
Collapse
Affiliation(s)
- Anna Alieva
- Deputy Chief Physician, Republican Specialized Scientific and Practical Medical Center of Endocrinology Named After Academician Ya. Kh. Turakulov of the Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan
- Corresponding Author: Deputy Chief Physician, Republican Specialized Scientific and Practical Medical Center of Endocrinology Named After Academician Ya. Kh. Turakulov of the Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan.
| | - Anvar Alimov
- Deputy Minister, Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan
| | - Feruza Khaidarova
- Deputy Director, Republican Specialized Scientific and Practical Medical Center of Endocrinology Named After Academician Ya. Kh. Turakulov of the Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan
| | - Saidiganikhoja Ismailov
- Head of the Department of Endocrinology with Pediatric Endocrinology, Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan
| | - Gulnara Rakhimova
- Head of the Department of Endocrinology, Center for the Development of Professional Qualifications of Medical Workers, Tashkent, Uzbekistan
| | - Dilorom Nazhmutdinova
- Head of the Department of Endocrinology, Tashkent Medical Academy, Tashkent, Uzbekistan
| | - Barno Shagazatova
- Department of Internal Medicine, Tashkent Medical Academy, Tashkent, Uzbekistan
| | - Victoria Tsareva
- Chief Physician, Tashkent City Endocrinological Dispensary, Tashkent, Uzbekistan
| |
Collapse
|
4
|
Drapkina OM, Karamnova NS, Kontsevaya AV, Gorny BE, Dadaeva VA, Drozdova LY, Yeganyan RA, Eliashevich SO, Izmailova OV, Lavrenova EA, Lischenko OV, Skripnikova IA, Shvabskaya OB, Shishkova VN. Russian Society for the Prevention of Noncommunicable Diseases (ROPNIZ). Alimentary-dependent risk factors for chronic non-communicable diseases and eating habits: dietary correction within the framework of preventive counseling. Methodological Guidelines. КАРДИОВАСКУЛЯРНАЯ ТЕРАПИЯ И ПРОФИЛАКТИКА 2021. [DOI: 10.15829/1728-8800-2021-2952] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The methodological guidelines are developed as a practical document for medical specialists working in the field of preventive medicine, in order to expand and improve the provision of this type of medical service to the adult population. The methodological guidelines include an informational and informative part for medical specialists and a practical part for patients, presented in the format of memos, contain the main sections-healthy nutrition, correction of eating habits, issues of modifying the diet for the main alimentary-dependent risk factors for chronic non-communicable diseases, such as arterial hypertension, obesity, disorders of lipid, carbohydrate and purine metabolism, a decrease in bone mineral density. They are intended for medical specialists working in the field of prevention, for doctors and secondary medical personnel of offices and departments of medical prevention, public health and medical prevention centers, healthy lifestyle specialists, teachers of medical educational institutions, for specialists who develop and implement educational programs for patients, as well as for medical specialists of a therapeutic profile.
Collapse
Affiliation(s)
- O. M. Drapkina
- National Medical Research Center for Therapy and Preventive Medicine
| | - N. S. Karamnova
- National Medical Research Center for Therapy and Preventive Medicine
| | - A. V. Kontsevaya
- National Medical Research Center for Therapy and Preventive Medicine
| | - B. E. Gorny
- National Medical Research Center for Therapy and Preventive Medicine
| | - V. A. Dadaeva
- National Medical Research Center for Therapy and Preventive Medicine
| | - L. Yu. Drozdova
- National Medical Research Center for Therapy and Preventive Medicine
| | - R. A. Yeganyan
- National Medical Research Center for Therapy and Preventive Medicine
| | - S. O. Eliashevich
- National Medical Research Center for Therapy and Preventive Medicine
| | - O. V. Izmailova
- National Medical Research Center for Therapy and Preventive Medicine
| | - E. A. Lavrenova
- National Medical Research Center for Therapy and Preventive Medicine
| | - O. V. Lischenko
- National Medical Research Center for Therapy and Preventive Medicine
| | - I. A. Skripnikova
- National Medical Research Center for Therapy and Preventive Medicine
| | - O. B. Shvabskaya
- National Medical Research Center for Therapy and Preventive Medicine
| | - V. N. Shishkova
- National Medical Research Center for Therapy and Preventive Medicine
| |
Collapse
|
5
|
Karonova TL, Mayorov AY, Magruk MA, Zyangirova ST, Grigoryeva IV, Khmelnitski OK, Myshkovets A, Parfenova TM, Mosikian AA, Drai RV. Safety and efficacy of GP40071 compared with originator insulin aspart (NovoRapid ® Penfill ®) in Type 1 diabetes mellitus. J Comp Eff Res 2021; 10:763-775. [PMID: 33928797 DOI: 10.2217/cer-2020-0208] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Aim: To compare safety and efficacy of GP40071 insulin aspart (GP-Asp) and NovoRapid® (NN-Asp). Materials & methods: This randomized open-label, active-controlled, 26-week non-inferiority Phase III clinical trial enrolled 264 Type 1 diabetes mellitus patients (HbA1c: 7.1-12.0%) randomized 1:1 to once daily GP-Asp (n = 132) or NN-Asp (n = 132). The primary safety end point was immune response at week 26. Results: The groups were similar in frequency of immune response (p = 0.323) and in other safety end points. Mean HbA1c change from baseline was -0.57% for GP-Asp and -0.56% for NN-Asp and did not differ between groups (p = 0.955). Intergroup mean difference of HbA1c level change (95% CI) at week 26 from baseline was 0.00 (-0.26, 0.25) %. Insulin doses, fasting plasma glucose levels and seven-point glucose profiles were similar between groups (p > 0.05). The number of patients experiencing hypoglycemic episodes did not differ between the groups (p = 0.497). Conclusion: GP-Asp demonstrated similar safety and efficacy. Trial registration number: NCT04079413 (ClinicalTrials.gov).
Collapse
Affiliation(s)
- Tatiana L Karonova
- Institute of Endocrinology, Almazov National Medical Research Center, Saint Petersburg, Russia
| | | | - Maxim A Magruk
- Clinical Trial Department, R&D Center, GEROPHARM, Saint-Petersburg, Russia
| | | | - Irina V Grigoryeva
- Clinical Trial Department, R&D Center, GEROPHARM, Saint-Petersburg, Russia
| | - Oleg K Khmelnitski
- Department of Therapy, Saint-Petersburg University, Saint-Petersburg, Russia
| | - Anton Myshkovets
- Clinical Trial Department, R&D Center, GEROPHARM, Saint-Petersburg, Russia
| | - Tatyana M Parfenova
- Krasnoyarsk State Medical University named after Professor VF Voyno-Yasenetskiy, Krasnoyarsk, Russia
| | - Anna A Mosikian
- Clinical Trial Department, R&D Center, GEROPHARM, Saint-Petersburg, Russia
| | - Roman V Drai
- Clinical Trial Department, R&D Center, GEROPHARM, Saint-Petersburg, Russia
| |
Collapse
|
6
|
Mayorov AY, Mosikian AA, Alpenidze DN, Makarenko IE, Orlova VL, Lunev IS, Verbovaya MV, Zinnatulina BR, Khokhlov AL, Drai RV. Efficacy and safety of GP40021 insulin lispro biphasic compared with Humalog Mix 25 in Type 2 diabetes mellitus patients. J Comp Eff Res 2020; 10:55-66. [PMID: 33355484 DOI: 10.2217/cer-2020-0064] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Aim: To compare safety (immunogenicity) and efficacy of a biosimilar insulin GP-Lis25 and a reference insulin Ly-Lis25 (Humalog Mix 25) in Type 2 diabetes mellitus (T2D) patients. Materials & methods: This randomized open-label, 26-week clinical trial enrolled 210 T2D patients, randomized 1:1 to twice-daily GP-Lis25 or Ly-Lis25. The primary end point was immune response at 26th week. Noninferiority margin for HbA1c was 0.4%. Results: Immune response frequency was similar in GP-Lis25 and Ly-Lis25 groups both at week 12 (p = 0.651) and 26 (p = 0.164). The difference of HbA1c change at week 26 was (95% CI) 0.01 (-0.27-0.28)%. Fasting plasma glucose, seven-point glucose profile and insulin dose were similar between groups. Safety did not differ between groups. Conclusion: GP-Lis25 and Ly-Lis25 demonstrated similar safety and efficacy. ClincalTrials.gov identifier: NCT04023344.
Collapse
Affiliation(s)
| | - Anna A Mosikian
- Department of Clinical trial, OOO GEROPHARM, Saint Petersburg, Russia
| | - Diana N Alpenidze
- Department of Endocrinology, City Outpatient Clinic No. 117, Saint Petersburg, Russia
| | - Igor E Makarenko
- Department of Clinical trial, OOO GEROPHARM, Saint Petersburg, Russia
| | - Valeria L Orlova
- Department of Endocrinology, City Hospital No. 2, Saint Petersburg, Russia
| | - Ivan S Lunev
- Department of Clinical trial, OOO GEROPHARM, Saint Petersburg, Russia
| | | | | | - Alexander L Khokhlov
- The Chair of Clinical Pharmacology, Yaroslavl State Medical University, Yaroslavl, Russia
| | - Roman V Drai
- Department of Clinical trial, OOO GEROPHARM, Saint Petersburg, Russia
| |
Collapse
|
7
|
Karonova TL, Mosikian AA, Mayorov AY, Makarenko IE, Zyangirova ST, Afonkina OA, Belikova TM, Zalevskaya AG, Khokhlov AL, Drai RV. Safety and efficacy of GP40061 compared with originator insulin glargine (Lantus ®): a randomized open-label clinical trial. J Comp Eff Res 2020; 9:263-273. [PMID: 32027167 DOI: 10.2217/cer-2019-0136] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Aim: To compare safety (immunogenicity) and efficacy of GP40061 insulin glargine (GP-Gla) and Lantus® (Sanofi glargine, Sa-Gla) in people with diabetes mellitus. Materials & methods: This randomized open-label, 26-week clinical trial enrolled 180 Type 1 diabetes mellitus patients (HbA1c 6.5-12.0%), randomized 1:1 to once daily GP-Gla (n = 90) or Sa-Gla (n = 90). The primary end point was immune response at 26th week. Results: The frequency of immune response was similar in GP-Gla and Sa-Gla (p = 1.000). Groups were similar in terms of other safety end points. Mean HbA1c change from baseline was -0.66% for GP-Gla and -0.77% for Sa-Gla, and did not differ between groups (p = 0.326). Insulin doses, fasting plasma glucose and seven-point glucose profiles were similar between groups. Conclusion: GP-Gla and Sa-Gla demonstrated similar safety and efficacy. ClinicalTrials.gov Identifier: NCT04022993.
Collapse
Affiliation(s)
- Tatiana L Karonova
- Institute of Endocrinology, Almazov National Medical Research Center, Saint-Petersburg, Russia
| | - Anna A Mosikian
- Clinical Trials Department, OOO GEROPHARM, Saint-Petersburg, Russia
| | - Alexander Y Mayorov
- Diabetes Prognosis and Innovation Department, Endocrinology Research Centre, Moscow, Russia
| | - Igor E Makarenko
- Clinical Trials Department, OOO GEROPHARM, Saint-Petersburg, Russia
| | | | - Olena A Afonkina
- Clinical Trials Department, OOO GEROPHARM, Saint-Petersburg, Russia
| | | | - Alsu G Zalevskaya
- Department of Endocrinology, First Pavlov State Medical University, Saint-Petersburg, Russia
| | - Alexander L Khokhlov
- Clinical Pharmacology Department, Yaroslavl State Medical University, Yaroslavl, Russia
| | - Roman V Drai
- Clinical Trials Department, OOO GEROPHARM, Saint-Petersburg, Russia
| |
Collapse
|